Ananda Devices names Keith Olson CEO to drive U.S. expansion

Ananda Devices appointed Life Science executive Dr. Keith R. Olson as chief executive officer effective immediately as the company prepares to expand operations in the United States. Founder Dr. Margaret Magdesian will shift to chief science officer while the company pushes its microphysiological systems into broader commercial use.

Why it matters: - Ananda Devices is moving from technology development toward commercial scale as demand rises for New Approach Methodologies in life sciences. - The leadership change is meant to support U.S. expansion, broader sales growth and manufacturing growth in the United States. - The company says its human-relevant systems are designed to reduce reliance on animal models and generate more predictive preclinical data.

What happened: - Ananda Devices appointed Dr. Keith R. Olson as chief executive officer effective immediately. - Founder Dr. Margaret Magdesian will transition from CEO to chief science officer. - The company announced the change on September 11, 2026. - Ananda Devices is based in Laval, Quebec, and is planning to expand operations to the United States.

The details: - Ananda Devices develops and manufactures microphysiological systems that model neuromuscular and neuronal physiology. - The company focuses on New Approach Methodologies, or NAMs, in the life sciences market. - Dr. Olson has held leadership roles at Corning, Fujifilm and Life Technologies. - Dr. Olson has experience commercializing advanced cell-based products. - Dr. Olson has led teams that launched more than 700 products and services. - The company’s two lead products, NeuroHTS™ and NeuroMuscle™, were launched at the beginning of 2026. - Ananda Devices was founded in 2016 as a spinout from McGill University. - The company serves drug discovery, disease modeling, toxin testing, food safety and medical countermeasure development. - Ananda Devices offers both products and services. - The company’s strategic objectives include global expansion of product sales, manufacturing expansion in the United States and delivery of advanced cell biology solutions across multiple market segments. - The company’s products aim to provide more predictive human neuronal models to accelerate discovery. - Ananda Devices aligns its work with New Approach Methods and the FDA Modernization Act. - More information is available on the company’s LinkedIn page.

Between the lines: - The appointment suggests Ananda Devices is preparing for a more commercial and U.S.-focused growth phase. - Dr. Olson’s background in large life science organizations and product launches signals a push to scale sales and operations. - The board framed the move as part of a broader shift from innovation to commercial success. - The company is positioning NAMs as a practical alternative for faster, safer and more effective treatment development.

What's next: - Ananda Devices plans to expand product sales globally. - The company also plans to expand manufacturing in the United States. - Dr. Olson is expected to lead business expansion while Dr. Magdesian focuses on advancing the company’s dual-use technology. - The company will continue targeting life science customers adopting NAM-based workflows.

The bottom line: - Ananda Devices is betting that new leadership will help turn its NAM technology into a larger U.S. business and a wider commercial platform.